Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
- 24 January 2006
- journal article
- research article
- Published by Springer Nature in Journal of Human Genetics
- Vol. 51 (3), 249-253
- https://doi.org/10.1007/s10038-005-0354-5
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenBlood, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivityHuman Molecular Genetics, 2005
- Common VKORC1 and GGCX polymorphisms associated with warfarin doseThe Pharmacogenomics Journal, 2005
- Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1Thrombosis and Haemostasis, 2005
- Translation of pharmacogenomics and pharmacogenetics: a regulatory perspectiveNature Reviews Drug Discovery, 2004
- Identification of the gene for vitamin K epoxide reductaseNature, 2004
- A high-throughput SNP typing system for genome-wide association studiesJournal of Human Genetics, 2001
- Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genesJournal of Human Genetics, 2001
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsChemical Research in Toxicology, 1992